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Liver fatty acid binding protein is a member of the fatty acid binding group of proteins that are involved in the intracellular transport of
bioactive fatty acids and participate in intracellular signalling pathways, cell growth and differentiation. In this study we have used
proteomics and immunohistochemistry to determine the changes in liver fatty acid binding protein in colorectal neoplasia.
Comparative proteome analysis of paired samples colorectal cancer and normal colon identified consistent loss of liver fatty acid
binding protein (L-FABP) in colorectal cancer compared with normal colon. To identify the changes in liver fatty acid binding protein
expression during colorectal cancer development and progression the cell-specific expression of L-FABP was determined by
immunohistochemistry in a series of colorectal cancers and colorectal adenomas. Decreased L-FABP immunoreactivity was
significantly associated with poorly differentiated cancers (Po0.001). In colorectal adenomas there was a significant trend towards
decreased staining of L-FABP in the larger adenomas (Po0.001). There was consistent L-FABP immunostaining of normal surface
colonocytes. This study demonstrates that loss of L-FABP occurs at the adenoma stage of colorectal tumour development and also
indicates that L-FABP is a marker of colorectal cancer differentiation.
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The fatty acid binding proteins are a group of low molecular
weight proteins involved in the intracellular transport of long-
chain bioactive fatty acids including linoleic acid and its
derivatives such as arachidonic acid (Glatz and van der Vusse,
1996; Hertzel and Bernlohr, 1998). The designation of each of these
proteins has been derived from the tissue from which it was
originally isolated and key members of this group of proteins
include liver fatty acid binding protein, intestinal fatty acid
binding protein and epidermal fatty acid binding protein.
Individual fatty acid binding proteins show specific lipid-binding
profiles and distinct patterns of tissue and cell-type specific
expression (Veerkamp et al, 1999; Richieri et al, 2000; Duplus and
Forest, 2002). Specific regulatory mechanisms operate for each
fatty acid binding protein.
These proteins play a central role in the solubilisation and the
intracellular compartmentalisation of fatty acids, thus facilitating
the cellular uptake and intracellular trafficking and processing of
fatty acids (Veerkamp et al, 1999; Storch and Thumser, 2000).
Fatty acid binding proteins play an active part in fatty acid-
mediated signal transduction pathways and regulation of gene
expression (Hertzel and Bernlohr, 1998). As a result, fatty acid
binding proteins are involved in modulating cell division (Sorof,
1994), cell growth and differentiation (Schroeder et al, 2001) and
also by preventing high intracellular fatty acid concentrations,
protect cells against the cytotoxic effects of fatty acids (Glatz et al,
1997).
In view of the role of fatty acid binding proteins in a variety of
key physiological functions it has been proposed that the
alterations that occur in individual fatty acid binding protein
expression during tumour development and progression (Celis
et al, 1996; Jing et al, 2000) may contribute to tumorigenesis.
Additionally, it has been suggested that the expression of
individual fatty acid binding proteins in tumours may also serve
as useful diagnostic markers and novel therapeutic targets (Das
et al, 2001).
We have been performing proteomic studies to identify changes
in protein expression in colorectal cancers (Lawrie and Murray,
2002) and have discovered that the expression of one member of
the family of fatty acid binding proteins namely liver fatty acid
binding protein (L-FABP) is consistently lost in colorectal cancer.
The cell-specific expression of L-FABP has been determined using
immunohistochemistry in normal colon, adenomas and carcino-
mas. Examining the expression of L-FABP at different stages of
tumour development reveals that L-FABP shows loss at the
adenoma stage of colorectal tumour development.
MATERIALS AND METHODS
Tissue samples
Proteomic analysis was performed on 20 matched pairs of Dukes’
C colorectal cancers and normal colorectal tissue samples obtained
from primary colorectal cancer resections and which had been
stored in the Aberdeen colorectal tumour bank. None of the
patients in this study had received any chemotherapy or
radiotherapy prior to surgery. The project had the approval of
the local research ethics committee. Representative samples of
viable tumour and normal colorectal mucosa (obtained at least
5cm from tumour) were dissected from colorectal cancer excision
specimens within 30min of surgical removal. Dissected samples
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ywere immediately frozen in liquid nitrogen and stored at  801C
prior to analysis (Table 1).
Immunohistochemistry for L-FABP was performed on formalin
fixed wax embedded colorectal cancer samples obtained from
patients who had undergone elective surgery for colorectal cancer
(n¼249) and were also selected from the Aberdeen colorectal
tumour bank. These cases have been extensively phenotyped for a
range of markers as previously described (McKay et al, 2000, 2002;
Leeman et al, 2002) and include the samples used for proteome
analysis. Detailed clinico-pathological data (Dukes’ stage, degree of
primary tumour differentiation, site of primary tumour, patient
age, and gender) are shown in Table 2. Immunohistochemistry was
also performed on formalin fixed wax embedded sections of
colorectal adenomas (n¼38 consisting of 19 tubular adenomas, 16
tubulo-villous adenomas and three villous adenomas; six adeno-
mas less than 5mm in size, 16 adenomas of 5–10mm in size and
16 adenomas greater than 10mm in size).
TWO-DIMENSIONAL GEL ELECTROPHORESIS
Lysis buffer preparation
Lysis buffer was prepared according to our established protocols
(Lawrie et al, 2001a) and contained urea (42% wv
 1); thiourea
(15% wv
 1); Chaps [3-(3-cholamidopropyl)dimethylammonio-1-
propanesulphonate] (4% wv
 1); N-decanoyl-N-methylglucamine
(Mega 10, 1% wv
 1), 1-O-Octyl-b-D-glucopyranoside (OBG, 1%
wv
 1), Triton X-100 (polyoxyethylene-p-isooctylphenol) (0.5%
vv
 1); Tris [Tris(hydroxymethyl)aminomethane] (0.5% wv
 1);
DTT (dithiothreitol) (0.8% wv
 1); IPG 3-10 NL (immobilised pH
gradient) buffer (1% vv
 1), b-mercaptoethanol (1% vv
 1),
tributylphosphine (0.02% vv
 1). All chemicals were obtained
from Amersham Biosciences, UK, with the exception of OBG
(Aldrich, UK) and Mega 10 (Sigma, UK).
Isoelectric focusing
Frozen sections (10mm in thickness) of tumour and normal were
cut using a cryostat and 30 10-mm sections of normal tissue or 30
10-mm sections of tumour tissue were solubilised in lysis buffer
(Lawrie et al, 2001a). One section from each tumour and normal
sample was stained with haematoxylin and eosin to confirm the
morphology; an assessment of tumour cellularity was also made of
each tumour sample to ensure that each of those samples
contained a high proportion of tumour cells. In total, 500mgo f
normal and tumour sample, respectively, were loaded, in duplicate,
into Immobiline Dry strip holders and Immobiline Drystrips, pI 3-
10 NL (Amersham Biosciences), were placed into the strip holders.
Strips were incubated overnight at room temperature to allow
sample absorption. After incubation strips were removed, and
strip holders were cleaned and small pieces of dampened electrode
strips were then placed over the electrodes in the strip holders to
help absorb excess salt during the first dimension focusing stage.
The strips were then placed back into the strip holders and covered
with dry strip cover fluid (Amersham Biosciences).
The first dimension focusing was carried out on an IPGPhor
system under the following conditions: 30min at 20V, 1.5h at
200V, 1.5h gradient to 3500V, 35h at 3500V, at 151C. After
completion of focusing the strips were equilibrated for 30min in
equilibration buffer containing urea (36% wv
 1); 0.5 M Tris-HCl,
pH 6.9 (20% vv
 1); 20% SDS (dodecyl sulphate, sodium salt) (20%
vv
 1); DTT (0.4% wv
 1); glycerol (30% vv
 1). Strips were
equilibrated for a further 30min in equilibration buffer where
DTT was replaced by iodoacetamide (1% wv
 1). All chemicals
were obtained from Amersham Biosciences.
Proteins were separated in the second dimension according to
their molecular weight using 7cm NuPAGE 4–12%, 1 well, Bis-Tris
gel (Invitrogen, Paisley, UK). First dimension strips were attached
to the second dimension gel with a 4% low melting point agarose
solution (Amersham Biosciences). Normal and tumour samples
from the same patient were run in the same gel tank to account for
any differences caused by gel electrophoresis. Gels were run at a
constant 120V until the bromophenol dye front reached the end of
the gel.
Proteins were visualised using a Colloidal Blue Staining Kit
(Invitrogen, Paisley, UK) used according to the manufacturer’s
protocol.
Detection of differential protein expression
Gels were destained using HPLC-grade water with microwave
heating. Destained gels were immediately photographed to
produce a black and white image. Gel photographs were scanned
to produce a computer image, which was then enlarged and
printed onto sheets of acetate. Overlaying the normal and tumour
acetate gel pictures allowed proteins that were differentially
Table 1 Clinicopathological characteristics of the cases used for
proteome analysis. All the cases were Dukes’ C colorectal cancers
Characteristic Number
Gender Male, n¼10
Female, n¼10
Age o55 years, n¼7
X55 years, n¼13
Site Proximal, n¼9
Distal, n¼10
Rectum, n¼1
Tumour differentiation Well, n¼0
Moderate, n¼19
Poor, n¼1
Table 2 Clinico-pathological characteristics of the colorectal cancer
cases studied by immunohistochemistry
Characteristic Number (%)
Gender
Male 133 (53.4)
Female 116 (46.6)
Age, years
Range 32–91
Mean 68
Median 69
Site
a
Proximal colon 90 (36.1%)
Distal colon 99 (39.8%)
Rectum 60 (24.1%)
Dukes’ stage
A 32 (12.9%)
B 123 (49.4%)
C 94 (37.7%)
Tumour differentiation
Well 8 (3.2%)
Moderate 205 (82.3%)
Poor 36 (14.5%)
aProximal colon tumours arose proximal to the splenic flexure, and distal colon
tumours arose distal to this site.
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yexpressed to be detected. Differentially expressed protein spots
were cut from the gel in preparation for identification by mass
spectrometry.
Identification of differentially expressed proteins
Individual proteins were identified by peptide mass mapping.
Protein spots were cut from the gel, washed to remove Coomassie
stain, reduced with DTT, alkylated with iodoactetamide and then
digested with trypsin. The resultant tryptic peptides were extracted
from the gel pieces under full automation (Pro-Gest Robot,
Genomic Solutions), desalted using microporous tips (Millipore)
deposited onto a sample plate along with a matrix chemical (a-
cyano-4-hydroxycinnamic acid) under full automation (Pro-MS,
Genomic Solutions). The masses of the tryptic fragments were
determined by Matrix Assisted Laser Desorption Ionisation Time
of Flight Mass Spectrometry (MALDI-TOF MS) using a PerSeptive
Biosystems Voyager-DE STR mass spectrometer. To identify the
original protein, the masses of the tryptic peptides were entered
into the MS-Fit database-searching program. The database search
was restricted to human proteins with no constraints on either the
molecular weight or the isoelectric point of the protein. A clear
difference in statistical score between the proteins ranked first and
second in the results list had to be obtained in order to confirm
that the correct protein was identified.
Immunohistochemistry
Immunohistochemistry was performed using a mouse monoclonal
antibody to L-FABP (Novocastra, Newcastle-upon-Tyne, UK) at a
dilution of 1:200. A Dako TechMatet 500 autostainer was used to
immunostain 4mm thick formalin fixed wax embedded sections
with the L-FABP antibody. A prior antigen retrieval step in boiling
10mM citrate buffer pH 6 for 20min was performed. Biotinylated
goat anti-mouse secondary antibody, a complex of avidin with
horseradish peroxidase (HRP) and diaminobenzidine (DAB) were
used as the detection-staining system. The cellular localisation of
L-FABP immunoreactivity was determined and scored for both
intensity (negative, weak, moderate and strong) and proportion (0,
1–5, 6–25, 26–50, 51–75 and 76–100%) of stained cells as
previously described (Leeman et al, 2002; McKay et al, 2002). To
allow comparison of L-FABP immunostaining with pathological
stage and survival for each cancer integer values were assigned to
the scores of intensity (0–3) and proportion of tumour cells
stained (0–5). These values were multiplied together to provide a
single L-FABP score as previously described (Leeman et al, 2002).
Statistical analysis was performed with SPSS v10 for Windows 95t.
RESULTS
Proteomic analysis
Protein expression profiles were generated from 20 pairs, in
duplicate, of normal mucosa and Dukes’ C colorectal cancers.
Protein profiles were reproducible with replicate samples taken
from the individual patients, but also when profiles were compared
with samples taken from other patients. Between 400 and 500
distinct proteins spots could be detected on each colloidal
Coomassie blue stained mini gel (Figure 1).
L-FABP was found to be consistently decreased in all 20 tumour
samples. The masses of the tryptic peptides were entered into the
MS-Fit database searching program, the results of which can be
seen in Table 3. In the example data shown, 18 of the
experimentally obtained peptides were matched, with better than
50ppm accuracy, to the sequence of L-FABP, which resulted in a
coverage of 96% of the L-FABP amino-acid sequence. From the ‘in-
depth’ database search results (Table 4) it was also observed that
the N-terminus of L-FABP was acetylated.
L-FABP IMMUNOHISTOCHEMISTRY
Colorectal carcinomas
In colorectal cancers L-FABP was observed in tumour cells while
no immunoreactivity was identified in stromal cells, endothelial
cells or inflammatory cells. The distribution of intensity and
proportion of cells showing L-FABP immunoreactivity is sum-
marised in Tables 5 and 6. In those tumours that showed positive
tumour cell staining the immunoreactivity for L-FABP usually
occurred in patches or clusters (Figure 2) while other areas of
tumour were negative. There was both cytoplasmic and nuclear
staining for L-FABP.
There was a statistically significant association of less L-FABP
immunoreactivity in poorly differentiated tumours (w
2¼18.2,
Po0.001). There was no relationship between L-FABP immunor-
eactivity and either tumour stage or overall survival.
Colorectal adenomas
All the adenomas studied showed some L-FABP immunoreactivity
with both nuclear and cytoplasmic immunoreactivity for L-FABP
(Figure 2). There was a significant trend towards larger adenomas
showing a smaller proportion of positively stained adenomatous
epithelium (w
2¼24.3, Po0.001, Table 7).
Normal colon
There was strong immunostaining of the surface epithelial cells of
normal colon. Immunoreactivity for L-FABP extended down the
upper half of the crypt epithelial cells while there was no staining
of the basal crypt epithelial cells. There was consistent staining of
both nuclei and cytoplasm. Other cell type including stromal cells,
endothelial cells and chronic inflammatory cells did not stain in
normal colon (Figure 2).
DISCUSSION
A pathway of genetic changes occurring in colorectal cancer
development has been well described (Ilyas et al, 1999). However,
it is now clear that there are multiple genetic pathways of
colorectal cancer development (Smith et al, 2002; Zhang et al,
Figure 1 Representative 2D gel showing the proteins expressed by a
sample of (A) normal colon tissue, (B) colorectal cancer tissue. A section
of each of the normal (C) and tumour (D) gels have been enlarged to
show the loss of L-FABP in the tumour sample.
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ment is probably only involved in a minority of colorectal cancers.
The advent of proteomics now allows the changes in protein
expression in colorectal cancer development and progression to be
studied. In a recent overview of proteomics in cancer research we
highlighted the key role of this technology in identifying changes
in tumour protein expression (Lawrie et al, 2001b). We indicated
both the rationale and the necessity to combine proteomics with
other investigative techniques to allow the biological, pathological
and clinical significance of those protein changes to be established
(Lawrie et al, 2001b). This often requires the use of larger samples
sizes and also allows the use of a wider range of clinical samples
than may be used in proteomics. In this proof-of-principle study
we have identified by proteomics the decrease of L-FABP in locally
advanced colorectal cancer. We have then determined the
pathological significance of altered L-FABP in a large series of
colorectal cancers and delineated the changes that occur in
L-FABP expression during colorectal cancer development and
progression. The analysis of other alterations in protein expression
in colorectal cancer that we identified is the subject of other
manuscripts.
L-FABP has a role in several important physiological functions
including intracellular signalling, control of cell division and cell
differentiation and these functions are dysregulated in tumour
development and progression. In normal hepatocytes, L-FABP
mediates the stimulation of DNA synthesis and cell growth by
Table 3 Identification of L-FABP
MOWSE
score
Number of
matching
peptides
Percent
coverage
Protein MW
(Da) Protein pI
SwissProt
Accession no. Protein name
1045000 18 96 14209 6.6 P07148 Liver fatty acid- binding protein
462 4 32 18013 7.7 P05092 Peptidyl-prolyl cis–trans isomerase A
361 4 43 12902 6.2 P23763 Vesicle-associated membrane protein 1
Example of an MS-Fit database search showing the identification of L-FAPB. The MOWSE score is much higher (225 times higher) for L-FABP compared with the next protein
score. The ‘MOWSE score’ is a score based on how many peptides have been matched to the protein in the database and the accuracy of those matches, the higher the
MOWSE score the better the hit; ‘no. of matching peptides’ is the number of experimentally obtained peptides that have been matched to theoretical peptides in the database;
‘Percent coverage’ is the percentage of the protein sequence covered by the matched peptides. ‘Protein MW and pI’ are the theoretical molecular weights and isoelectric points
of the proteins; ‘Swissprot Accession no’ is an accession number in the SwissProt database that allows further information to be obtained about the identified protein; ‘protein
name’ shows the name of the identified protein.
Table 4 Detailed mass spectrometric analysis of L-FABP
m/z submitted MH
+ matched Delta (ppm) Modifications Start End Missed cleavages Database sequence
1210.70 1210.70 0 21 31 0 AIGLPEELIQK
1442.77 1442.78 5 37 49 1 GVSEIVQNGKHFK
1752.00 1752.03 17 21 36 2 AIGLPEELIQKGKDIK
1762.79 1762.81 12 7 20 0 YQLQSQENFEAFMK
1778.80 1778.81 1 1Met-ox 7 20 0 YQLQSQENFEAFMK
1791.92 1791.99 38 81 96 1 TVVQLEGDNKLVTTFK
2019.12 2019.15 16 79 96 2 VKTVVQLEGDNKLVTTFK
2147.11 2147.21 47 81 99 2 TVVQLEGDNKLVTTFKNIK
2248.15 2248.21 28 37 57 2 GVSEIVQNGKHFKFTITAGSK
2311.11 2311.07 18 AcetN 1 20 1 SFSGKYQLQSQENFEAFMK
2327.12 2327.07 25 AcetN 1Met-ox 1 20 1 SFSGKYQLQSQENFEAFMK
2381.13 2381.23 41 100 121 0 SVTELNGDIITNTMTLGDIVFK
2443.06 2443.10 18 58 78 0 VIQNEFTVGEECELETMTGEK
2537.33 2537.33 0 100 122 1 SVTELNGDIITNTMTLGDIVFKR
2553.28 2553.32 16 1Met-ox 100 122 1 SVTELNGDIITNTMTLGDIVFKR
2670.23 2670.26 13 58 80 1 VIQNEFTVGEECELETMTGEKVK
2686.37 2686.26 40 1Met-ox 58 80 1 VIQNEFTVGEECELETMTGEKVK
2970.50 2970.49 4 1Met-ox 7 31 1 YQLQSQENFEAFMKAIGLPEELIQK
An example of the MS-Fit database ‘in depth’ search results where ‘m/z submitted’ is the experimentally obtained tryptic masses, ‘MH
+ matched’ is the theoretical tryptic mass
obtained after theoretical digestion of L-FABP, which the experimental tryptic mass has been matched to, ‘delta ppm’ is the difference between the experimentally and
theorectically obtained tryptic masses. ‘Modifications’ identifies the modification on any peptide, where 1Met-ox is the oxidation of one methionine residue, and AcetN is the
acetylation of the N-terminus. ‘start’ & ‘end’ identifies the position of the tryptic peptide within the protein sequence. ‘Missed cleavages’ identifies how many times trypsin missed
a cleavage site. ‘Database sequence’ shows the sequence of the tryptic fragment matched in the database.
Table 5 The proportion of tumour cells in colorectal cancers showing
L-FABP immunoreactivity
Proportion of L-FABP positive
tumour cells Percentage (number) of tumours
Negative 18.5% (n¼46)
1–5% 13.3% (n¼33)
6–25% 20.1% (n¼50)
26–50% 19.3% (n¼48)
51–75% 23.3% (n¼58)
76–100% 5.6% (n¼14)
Table 6 Intensity of L-FABP immunostaining in colorectal cancer
Intensity Percentage (number) of tumours
Negative 18.5% (n¼46)
Weak 8.4% (n¼21)
Moderate 20.5% (n¼51)
Strong 52.6% (n¼131)
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ylong-chain fatty acids. (Glatz and van der Vusse, 1996). Evidence
for the involvement of fatty acid binding proteins in cell growth
and differentiation has been established through a series of studies
on the action of chemical carcinogens on rat liver. It was found
that the cellular content of L-FABP was markedly elevated during
normal as well as carcinogen-induced mitotic activity of hepato-
cytes (Custer and Sorof, 1984, 1985) and that L-FABP was also
specifically required in the induction of cell proliferation by two
specific classes of hepatocarcinogenic peroxisome proliferators
(Keler and Sorof, 1993; Khan and Sorof, 1994). A direct correlation
was found between the relative affinities of the various peroxisome
proliferators for L-FABP in vitro and their abilities to enhance
mitogenesis (Sorof, 1994). Compared with other fatty acid binding
proteins L-FABP has distinct fatty acid binding profile. In addition
to acting as a fatty acid receptor L-FABP is the target protein for
several genotoxic carcinogens (Sorof, 1994). Binding of these
carcinogens to L-FABP promotes mitogenesis and this protein has
also therefore been implicated in early tumour development (Khan
and Sorof, 1994; Sorof, 1994).
L-FABP expression has previously been examined in the small
intestine and colon of rats treated with 1,2-dimethylhydrazine,
which produces a predictable pattern of both small and large
bowel cancers (Davidson et al, 1993). This study found that there
was a 50-fold decrease in L-FABP mRNA abundance in colon
cancers compared with uninvolved mucosa. Immunocytochemical
analysis also revealed decreased L-FABP staining in the colonic
tumours, although mosaic clusters of L-FABP reactive tumour
cells that showed both nuclear and cytoplasmic staining were
often detected. The mosaic pattern of immunohistochemical
staining for L-FABP was also observed in rat foetal small
intestine and colon (Davidson et al, 1993). This led to the
proposal that the expression of L-FABP was developmentally
regulated and that L-FABP was involved in the promotion of
normal intestinal differentiation. It was also suggested that the
pathways involved in L-FABP regulation are disrupted in
transformed and dedifferentiated enterocytes (Davidson et al,
1993). Our immunohistochemical results also demonstrate a
patchy or ‘mosaic’ pattern of L-FABP positive tumour cells
staining and are consistent with previous findings in chemically
induced rat intestinal tumours (Davidson et al, 1993).
While 2D gel electrophoresis studies showed that L-FABP was
consistently present in samples of normal colon mucosa,
immunohistochemical studies highlighted its distribution and
showed that L-FABP was strongly present in the surface epithelium
and the crypt epithelium of the upper half of the crypt while it was
not detected in the epithelial cells of the lower half of the crypt.
This finding provides further support to the concept that L-FABP
is a marker of colonocyte differentiation as previously observed in
rat colon (Davidson et al, 1993).
The loss of L-FABP in colorectal neoplasms contrasts with the
finding in other tumour types. In prostate cancer L-FABP
mRNA and protein has been found to show markedly increased
expression in both primary tumours and in prostate cancer
derived cell lines (Das et al, 2001). Inhibition of L-FABP by
antisense oligonucleotides in prostate cancer decreases tumour
cell proliferation and promotes apoptosis. Expression of L-FABP
has also previously been observed in primary liver cancer with
L-FABP specifically localised to tumour cells. Higher frequency
of L-FABP expression occurs in hepatoblastomas compared with
hepatomas (Suzuki et al, 1990). Those observations in diverse
Figure 2 The immunohistochemical localisation of L-FABP in colon
cancer, colon adenomas and normal colon. In colon cancer there is patchy
staining of the tumour cells. (A) Tumour with a high proportion of tumour
cells staining positively for L-FABP while (B) is a tumour with a low
proportion of L-FABP positive tumour cells. The patchy or mosaic staining
for L-FABP is also demonstrated in (B).( C) Tumour that is negative for L-
FABP. A small tubular adenoma (D) showing patchy staining for L-FABP. In
a villous adenoma (E) there is only a small proportion of tumour cells
showing L-FABP immunoreactivity and the staining is in discrete groups of
cells. Immunohistochemical staining for L-FABP in normal colon is present
in the surface epithelium and the upper half of the crypt epithelium (F).
Table 7 Proportion of L-FABP immunoreactive positive cells in colorectal adenomas
L-FABP immunoreactivity Small adenomas (n¼6) Medium adenomas (n¼16) Large adenomas (n¼16)
Negative 0 0 0
1–5% 0 0 12.5% (n¼2)
6–25% 0 0 18.75% (n¼3)
26–50% 0 100% (n¼12) 62.5% (n¼10)
51–75% 100% (n¼6) 25% (n¼4) 6.25% (n¼1)
76–100% 0 0 0
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and presumably reflect tissue-specific regulatory mechanisms for
L-FABP.
In conclusion, we have identified by proteomics the loss of
L-FABP in colorectal cancer. We have determined the changes in
L-FABP that occur during colorectal cancer development and
progression, and have shown that its loss is an early stage event in
colorectal tumour development. L-FABP was also found to be a
marker of tumour differentiation in colorectal cancer. This study
provides the basis for the evaluation of other differentially
expressed proteins identified by colorectal cancer proteomics
and evaluate them in the appropriate clinico-pathological context.
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